Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings
AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3.
New Strong Buy Stocks for September 30th
MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.
ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe
AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.
New Strong Buy Stocks for September 13th
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
AngioDynamics Stock Falls Despite CE Mark for Auryon System
ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.
AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why
AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does AngioDynamics (ANGO) Have the Potential to Rally 77.03% as Wall Street Analysts Expect?
The mean of analysts' price targets for AngioDynamics (ANGO) points to a 77% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Should You Buy AngioDynamics (ANGO) After Golden Cross?
From a technical perspective, AngioDynamics, Inc. (ANGO) is looking like an interesting pick, as it just reached a key level of support. ANGO's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 74.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
New Strong Buy Stocks for July 29th
KRO, FUNC, PRG, ANGO and HGTY have been added to the Zacks Rank #1 (Strong Buy) List on July 29, 2024.
AngioDynamics: Lumpy Progress Is Still Progress
AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife generated double-digit year-over-year growth, while AlphaVac bounced back strongly on a sequential basis, and gross margin improved more than three points. Execution remains the key here, as Auryon, AlphaVac, and NanoKnife all have legitimate growth potential, but significant competition as well.
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.
